Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients

✍ Scribed by Barry R. Goughnour; William W. Arkinstall; John H. Stewart

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: English
• Weight: 441 KB
• Volume: 63
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19890601)63:11<2294::aid-cncr2820631139>3.0.co;2-x

✦ Synopsis

Immediate-release oral morphine, given every four hours in individually titrated doses, is effective in the control of severe cancer pain. To evaluate the analgesic efficacy of a controlled-release morphine sulfate preparation, MS Contin tablets (MSC, Purdue Frederick, Toronto, Ontario, Canada), after a single dose and under steady-state conditions, the authors compared MSC administered every 1 2 hours with morphine oral solution (MOS) administered every 4 hours in 17 adult cancer patients with chronic severe pain. In the single-dose evaluation, in which the patients were randomly assigned to receive MSC or MOS, there were no significant differences in analgesic efficacy or requirement for supplemental morphine between the two treatments. With both preparations, pain severity ratings increased toward the end of the 12hour, single-dose observation period and were higher than the pain scores reported after dose titration.